Latest Neuropathic pain Stories
SAN FRANCISCO, April 23, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2015 on Thursday, April 30, 2015, after
Phase 1 study to include additional cohorts with novel product candidate being developed for the treatment of neuropathic pain NEW YORK, April 16, 2015 /PRNewswire/ -- Relmada Therapeutics,
THE WOODLANDS, Texas, April 15, 2015 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
SAN FRANCISCO, April 13, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the 14th Annual Needham
NIH grant supports development of PNS system to advance prior federally-funded research CLEVELAND, April 6, 2015 /PRNewswire-USNewswire/ -- SPR® Therapeutics has received a $1.45M
- June re-launch with significantly expanded commercial resources NEWARK, Calif., April 2, 2015 /PRNewswire/ -- Depomed, Inc.
LONDON, April 1, 2015 /PRNewswire/ -- Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation SummaryLarge
GIA announces the release of a comprehensive global report on Pain Management Devices.
Novel product candidate being developed for the treatment of neuropathic pain demonstrates good safety profile even at higher doses NEW YORK, March 17, 2015 /PRNewswire/ -- Relmada
NEW YORK, March 16, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc.
- An armed gangster.